- Replimune’s shares crater as FDA rejects melanoma drug Fierce Biotech
- Replimune skin cancer therapy rejected by FDA, a sign of regulators’ hardened stance statnews.com
- Replimune drug rejected by FDA; Omega raises $647M biotech fund Yahoo Finance
- Replimmune Plummets Following FDA’s Surprise Rejection of Melanoma Treatment BioSpace
- Replimune Stock Plummets 75% After FDA Rejects Application for Skin Cancer Treatment Barron’s
Source link
